QSAR of Novel Chrysin Benzimidazole Derivatives for Potential Anti-Cancer Agents

Arun Kumar Rai; Keerti Sahu; Megha Chouhan; Abhishek Shrivastav; Shubhanshi Saxena

doi:10.37022/wjcmpr.v8i2.402

Authors

Arun Kumar Rai Assistant Professor, Department of Pharmaceutical Chemistry, Corporate Institute of Pharmacy, Bhopal, Madhya Pradesh, India. (462022)
Keerti Sahu Assistant Professor, People’s University, School of Pharmacy and research center, Bhopal, Madhya Pradesh, India. (462037)
Megha Chouhan Associate Professor, Mittal Institute of Pharmacy, Bhopal, Madhya Pradesh, India. (462038)
Abhishek Shrivastav Assistant Professor, Department of Pharmaceutical Chemistry, Corporate Institute of Pharmacy, Bhopal, Madhya Pradesh, India. (462022)
Shubhanshi Saxena Assistant Professor, Department of Pharmaceutical Chemistry, Corporate Institute of Pharmacy, Bhopal, Madhya Pradesh, India. (462022)

Abstract

The current study focuses on developing a Quantitative Structure-Activity Relationship (QSAR) model for novel chrysin-benzimidazole derivatives as possible anti-cancer drugs for hepatocellular carcinoma (HepG2 cell line). The biological activity of 21 substances was measured using IC₅₀ values, which were then converted to pIC₅₀ for better statistical analysis. Molecular structures were optimized with the semi-empirical PM3 method, and ChemOffice software was used to calculate several physicochemical characteristics. Multiple linear regression analysis was used to find relationships between molecular characteristics and biological activity. The created QSAR models revealed a strong link between structural features and anticancer efficacy, emphasizing the significance of descriptors such as molar refractivity, partition coefficient, and related factors. The validated model demonstrated satisfactory prediction ability on both the training and test sets. This study sheds light on the structural prerequisites for anticancer action, which may aid in the rational development of more effective benzimidazole-based medicinal medicines.

Keywords:

QSAR, Benzimidazole derivatives, Anti-cancer activity, HepG2 cell line

DOI

https://doi.org/10.37022/wjcmpr.v8i2.402

References

1. Chimento A, Sala M, Gomez-Monterrey IM, Musella S, Bertamino A, Caruso A, et al. Biological activity of 3-chloro-azetidin-2-one derivatives having interesting antiproliferative activity on human breast cancer cell lines. Bioorg Med Chem Lett. 2013;23:6401–6405.

2. Rui M, Rossi D, Marra A, Paolillo M, Schinelli S, Curti D, et al. Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor modulators, as potential anticancer agents. Eur J Med Chem. 2016;124:649–665.

3. Chandu B, Sowjanya M, Prapurna Chandra Y. a review on breast cancer in a young women and oppurnities in treatment. World Journal of Current Medical and Pharmaceutical Research. 2025 Feb 11:1-7.

4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

5. Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial. Am J Gastroenterol. 2013;108:425–432.

6. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma: how can outcomes be improved? Oncologist. 2010;15:42–52.

7. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma. Oncologist. 2006;11:790–800.

8. Shah I, Raytthatha N. A Brief Review on Breast cancer treatment and current challenges. World Journal of Current Medical and Pharmaceutical Research. 2021 Apr 18:27-31.

9. Dai X, Wang L, Deivasigamni A, Looi CY, Karthikeyan C, Trivedi P, et al. A novel benzimidazole derivative inhibits tumor growth via ROS-dependent JNK signaling pathway. Oncotarget. 2017;8:12831.

10. Townsend LB, Wise DS. The synthesis and chemistry of certain anthelmintic benzimidazoles. Parasitol Today. 1990;6:107–112.

11. Woolley DW. Some biological effects produced by benzimidazole and their reversal by purines. J Biol Chem. 1944;152:225–232.

12. Fang Y, Zhou H, Gu Q, Xu J. Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids. Eur J Med Chem. 2019;167:133–145.

13. Shimomura I, Yokoi A, Kohama I, Kumazaki M, Tada Y, Tatsumi K, et al. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents. Cancer Lett. 2019;451:11–22.

14. Peta S, Pallepati K. Synthesis and evaluation of anti-bacterial activity of benzimidazole derivatives. Journal of Modern Techniques in Biology and Allied Sciences. 2025 Jun 30:33-8.

15. Shingalapur RV, Hosamani KM, Keri RS. Synthesis and evaluation of antimicrobial and antitubercular activity of benzimidazoles. Eur J Med Chem. 2009;44:4244–4248.

16. Surineni G, Gao Y, Hussain M, Liu Z, Lu Z, Chhotaray C, et al. Design and synthesis of benzimidazole derivatives as inhibitors of Mycobacterium tuberculosis. MedChemComm. 2019;10:49–60.

17. Zhang HZ, Damu GL, Cai GX, Zhou CH. Design and antimicrobial evaluation of benzimidazole-type fluconazole analogues. Eur J Med Chem. 2013;64:329–344.

18. Hernandez-Luis F, Hernandez-Campos A, Castillo R, Navarrete-Vazquez G, Soria-Arteche O, Hernandez-Hernandez M, et al. Synthesis and biological activity of benzimidazole derivatives against protozoa. Eur J Med Chem. 2010;45:3135–3141.

19. Donapaneedi SN, Suresh KA, Chakraborty K, Valluru L. Invitro Antiproliferative Effect of Marine Macroalgae on Different Human Cancer Cell Lines. International Journal of Pharmaceutics and Drug Analysis. 2018;6(2):342-51.

20. Manju PT, Smith AA, Padmaja V. In Vivo Evaluation of Antiproliferative Activity of A Novel Benzimidazole De-rivative Against Daltons Lymphoma Ascitic in Swiss Albino Mice. International Journal of Pharmaceutics and Drug Analysis.;6(3):400-5.

21. Luo Y, Yao JP, Yang L, Feng CL, Tang W, Wang GF, et al. Design and synthesis of benzimidazole derivatives as inhibitors of hepatitis B virus. Bioorg Med Chem. 2010;18:5048–5055.

22. Singla P, Luxami V, Paul K. Benzimidazole scaffold for protein kinase inhibitors. RSC Adv. 2014;4:12422–12440.

23. Achar KC, Hosamani KM, Seetharamareddy HR. In vivo analgesic and anti-inflammatory activities of benzimidazole derivatives. Eur J Med Chem. 2010;45:2048–2054.

24. Refaat HM. Synthesis and anticancer activity of substituted benzimidazole derivatives. Eur J Med Chem. 2010;45:2949–2956.

25. Azam M, Khan AA, Al-Resayes SI, Islam MS, Saxena AK, Dwivedi S, et al. Synthesis and evaluation of benzimidazoles as anticancer agents. Spectrochim Acta A. 2015;142:286–291.

26. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. Suppression of hepatocellular carcinoma by albendazole. Cancer Lett. 2001;165:43–49.

27. Hsieh CY, Ko PW, Chang YJ, Kapoor M, Liang YC, Chu HL, et al. Design and synthesis of benzimidazole-chalcone derivatives as anticancer agents. Molecules. 2019;24:3259.

28. Rai AK, Singh P, Mishra M, Singour PK. Design, synthesis and biological evaluation of chalcone-bearing benzimidazole derivatives as anti-inflammatory agents. 2025;10(4):57-71.

29. Rai AK, Rathore M, Gupta M, Yadav N, Singh V. Network pharmacology and molecular docking approaches for herbal formulations. Int J Pharma Biosci. 2026;24–33.

30. Raikwar P, Rai AK, Yadav S, Rajput NS, Pandey S, Mishra M, et al. 2D QSAR of novel hybrid motifs for anticancer activity against MCF-7. J Drug Deliv Ther. 2026;16(4):109–119.

31. Wang Z, Deng X, Xiong S, Xiong R, Liu J, Zou L, Lei X, Cao X, Xie Z, Chen Y, Liu Y. Design, synthesis and biological evaluation of chrysin benzimidazole derivatives as potential anticancer agents. Natural product research. 2018 Dec 17;32(24):2900-9.

32. Singh AK, Patel J, Jain N, Singour PK. QSAR studies of 2-phenoxyacetamide analogues, a novel class of potent and selective monoamine oxidase inhibitors. Current Research in Pharmaceutical Sciences. 2017:109-16.